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Objectives: We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteris-
tics at baseline as well as with their response to first-line ART.
Methods: Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the
year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and
normalized by CD4! T cells. Linear correlation between pre-ART HIV DNA and other continuous markers
(HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson
correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to
study the association between pre-ART HIV DNA and time to viro-immunoclinical events.
Results: Pre-ART HIV DNA [median (IQR): 10 702 (3397–36 632) copies/106 CD4! T cells] was correlated with pre-
ART HIV RNA [R2"!0.44, (P,0.0001)], CD4! T cells [R2"#0.58, (P,0.0001)] and CD4/CD8 ratio [R2"#0.48,
(P,0.0001)], while weaker correlations were observed with CD8! T cells (R2"#0.20, P"0.01), IL-6 (R2"!0.16,
P"0.002) and soluble CD14 (R2"!0.09, P"0.05). Patients with higher pre-ART HIV DNA showed lower rate and
delayed virological response (defined as HIV RNA50 copies/mL), compared with those having lower HIV DNA
(67.2% for.10 000, 81.1% for 1000–10 000 and 86.4% for 10–1000 copies/106 CD4! T cells; P"0.0004). Higher pre-
ART HIV DNA was also correlated with increased risk of virological rebound (defined as HIV RNA.50 copies/mL) by
24 months (17.2% for .10 000, 7.4% for 1000–10 000 and 4.3% for 10–1000 copies/106 CD4! T cells; P"0.0048).
Adjusted HRs of all virological rebound definitions confirmed these findings (P0.02).
Conclusions: Pre-ART HIV DNA, along with HIV RNA and CD4! T cell count, should be considered as a new stag-
ing marker to better identify people at lower (or higher) risk of viral rebound following achievement of virological
suppression (50 copies/mL).
Introduction
HIV-1 is known to establish persistent infection through different
mechanisms, the main one being HIV-1 DNA persistence in infected
cells, such as CD4! T cells that remain the main contributor to viral
persistence and the major obstacle for cure strategies.1–6 Several
markers have been proposed to measure the viral burden in these
cells and among these total HIV DNA is a good candidate due to the
simplicity, accuracy and reproducibility of its quantification and the
small sample required.7–11 Total HIV DNA includes both integrated
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and unintegrated forms of HIV DNA, which can coexist in infected
cells and can actively participate in viral transcription, viral replica-
tion and pathogenesis.12,13 In the setting of drug-naive patients,
total HIV DNA has been shown to be a clinically relevant parameter
for disease progression,14–17 with a predictive power for AIDS or
death stronger than that of plasma HIV RNA.16 Recent studies also
suggest that total HIV DNA can predict the time and magnitude of
viral rebound in treatment-experienced patients after therapy inter-
ruption,17 as well as early virological failure in pretreated patients
receiving simplified regimens.18 In the setting of long-term effective
ART, total HIV DNA in CD4! T cells not only reflects the size of the
replication-competent viral load (VL),19,20 but has also been linked
to multiple treatment outcomes, such as therapeutic failure, re-
sidual viraemia and immune recovery,21,22 thus reinforcing the util-
ity of total HIV DNA monitoring in long-term treatment follow-up.
Very limited data are available regarding the prognostic value of
pretreatment HIV DNA to predict the chance of virological suppres-
sion and of long-term treatment outcome in patients starting
their first-line ART regimen.23–25 For this reason, this study aims to in-
vestigate the association between total HIV DNA (quantified by a
modified commercial assay at ART initiation) and other pre-ART viro-
immunoclinical parameters, as well as its prognostic value to predict
subsequent viral response in patients achieving first viral suppression.
Methods
Study population
This prospective study includes retrospective collected samples from
patients belonging to the ICONA Foundation Cohort, a multicentre Italian
cohort enrolling and prospectively following ART-naive HIV-infected
patients who participated in the original ICONA study.26 CD4! T cells and
CD8! T cell counts and VL measurements were performed on average
every 4 months (median 3.4, IQR 2.1–6.0); patients were monitored also for
other laboratory parameters (e.g. liver and kidney function, lipids), clinical
and treatment data. A biobank collecting plasma and blood cell samples at
baseline and yearly is also available.
Our analyses were limited to ART-naive patients who started an ART
regimen including at least three antiretroviral drugs after 1 January 2000
and having a clinical and viro-immunological follow-up of at least 1 year.
Each patient at ART initiation had available a stored PBMC aliquot and/or
whole blood and plasma samples, for HIV DNA and plasma biomarker
evaluation, respectively. All patients were also monitored by standard rou-
tine visits and evaluated for the development of AIDS, serious non-AIDS
events or death. The following diseases were considered serious non-AIDS
events: end-stage liver disease, end-stage renal disease, myocardial infarc-
tion, sepsis, non-AIDS-defining cancers and severe cardiovascular events.
All patients signed informed consent forms to participate in the ICONA
Foundation Study. The research study protocol was approved by local institu-
tional review boards and by the ethics committee of each participating centre.
Quantification of plasma HIV-1 RNA
Depending on methodologies available during 2000–16, plasma HIV RNA
was routinely determined using three different assays at the different par-
ticipating centres.27–29 Details are provided in the Supplementary Methods
(see Supplementary data at JACOnline).
Quantification of pre-ART HIV DNA
Total HIV DNA was quantified at University of Rome Tor Vergata before ART
initiation (time window for HIV DNA collection #12+1 weeks from ART
initiation) starting from a pellet of at least 1%106 PBMCs (range of 1%106 to
6%106) for 272 patients, and from 200lL of whole blood for 161 patients,
by using a modified version of the commercial COBAS AmpliPrep/COBAS
TaqMan HIV-1 Test v2.0, as previously reported.10 Detailed methodology is
provided in the Supplementary data.
Quantification of plasma biomarkers
We used commercially available ELISAs to quantify plasma levels of IL-6
and soluble CD14 (sCD14) (R&D Systems), according to the manufacturer
protocols.
Statistical analysis
Patients were ranked in three categories according to a priori chosen cut-offs
in the HIV DNA levels at ART initiation (pre-ART HIV DNA): 10–1000 copies/106
CD4! T cells; 1000–10 000 copies/106 CD4! T cells; and.10 000 copies/106
CD4! T cells.
Categorical factors at baseline were compared across HIV DNA groups
using the v2 test.
Virological suppression
Standard survival analysis based on Kaplan–Meier estimates was used to
evaluate the association between pre-ART HIV DNA levels and the time to
achieve virological suppression, defined as the first of two determinations
of plasma HIV RNA50 copies/mL. These analyses were performed on the
overall population (n"433).
Long-term treatment outcome
To evaluate the possible effect of pre-ART HIV DNA levels on the risk of viro-
logical rebound, we included in the analysis only participants who had
achieved virological suppression 50 copies/mL (n"397). Standard sur-
vival analysis based on Kaplan–Meier estimates was used to evaluate the
association between pre-ART HIV DNA and the time to achieve the following
primary endpoint: virological rebound, defined according to three different
HIV RNA cut-off values: (i) two confirmed plasma HIV RNA determinations
.50 copies/mL; (ii) two confirmed plasma HIV RNA determinations .200
copies/mL; and (iii) a single plasma HIV RNA.1000 copies/mL.
Secondary endpoints were: (i) an increase in CD4! T cell count of at
least 200 cells/mm3 from pre-ART levels; and (ii) AIDS diagnosis, serious
non-AIDS events or death. Kaplan–Meier curves were compared by means
of the Fleming–Harrington test.
Cox regression models were used to test the prognostic value of pre-
ART HIV DNA (fitted in the log10 scale) to predict long-term treatment out-
comes, after controlling for a number of identified potential confounders.
A similar analysis was performed to test the impact of pre-ART HIV RNA on
the same outcomes.
A detailed description of the statistical analyses used can be found in
the Supplementary data.
Statistical analyses were performed using SAS (version 9.4, SAS
Institute, Cary, NC, USA).
Results
Patient characteristics
Four-hundred and thirty-three patients were included in this ana-
lysis. Baseline patient characteristics according to HIV DNA strata
are shown in Table 1. The majority were male (n"350, 80.8%)
and MSM (n"194, 44.8%). The median age was 38 years (IQR
33–46 years).
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For a subset of individuals (n"7), for whom both blood samples
and PBMCs were available, we performed the total HIV DNA quan-
tification by both sources. Results of HIV DNA quantification nor-
malized for CD4 cells were comparable [median (IQR) HIV DNA
was 3.5 (3.2–4.6) log10 copies/10
6 CD4! T cells in blood samples
and 3.7 (3.4–4.7) log10 copies/10
6 CD4! T cells in PBMCs; P"0.13].
As per inclusion criteria, all patients were enrolled before ART
initiation and had a median plasma HIV RNA and a median HIV
DNA of 4.84 (IQR 4.32–5.35) log10 copies/mL and 10 702 (IQR
3397–36 632) copies/106 CD4! T cells, respectively. Median CD4!
T cell count was 297 (IQR 160–408) cells/mm3. The median (IQR)
year of sample collection (corresponding to the start of ART) was
2010 (2004–11). Data regarding ART, time to achieve virological
suppression (50 copies/mL) and genotypic susceptibility score
(GSS) of ART are shown in Table S1.
By stratifying patients according to pre-specified clinical cut-
offs for pre-ART HIV DNA, more than half of patients (n"227,
52.4%) had a total HIV DNA higher than.10 000 copies/106 CD4!
T cells, 37.4% (n"162) between 1000 and 10 000, and only 10.2%
(n"44) between 10 and 1000 copies/106 CD4! T cells. By corre-
lating pre-ART HIV DNA with other viro-immunological parame-
ters, higher plasma HIV RNA (P,0.0001), lower CD4! T cell count
(P,0.0001) and lower CD4/CD8 ratio (P,0.0001) at baseline were
more frequently observed in the patients with pre-ART HIV DNA
Table 1. Main characteristics of overall population
HIV DNA (per 1%106 CD4 cells)
Characteristics
10–1000 1000–10 000 .10 000
P value
Total
(n"44) (n"162) (n"227) (N"433)
Gender, n (%) 0.965
female 8 (18.2) 32 (19.8) 43 (18.9) 83 (19.2)
Mode of HIV transmission, n (%) 0.017
IVDU 4 (9.1) 14 (8.6) 25 (11.0) 43 (9.9)
homosexual contacts 26 (59.1) 86 (53.1) 82 (36.1) 194 (44.8)
heterosexual contacts 12 (27.3) 53 (32.7) 100 (44.1) 165 (38.1)
other/unknown 2 (4.5) 9 (5.6) 20 (8.8) 31 (7.2)
Ethnicity, n (%) 0.631
Black 3 (6.8) 6 (3.7) 12 (5.3) 21 (4.8)
Age, years 40 (33–50) 37 (31–43) 39 (33–47) 0.007 38 (33–46)
Viral RNA, log10 copies/mL 4.26 (3.56–4.67) 4.56 (4.18–5.00) 5.07 (4.71–5.54) ,0.001 4.84 (4.32–5.35)
HIV subtype 0.341
B 22 (50.0) 74 (45.7) 114 (50.2) 210 (48.5)
non-B 3 (6.8) 13 (8.0) 28 (12.3) 44 (10.2)
unknown 19 (43.2) 75 (46.3) 85 (37.4) 179 (41.3)
Time from seroconversion to sample, months 39 (21–146) 30 (14–55) 48 (15–87) 0.142 35 (15–79)
CD4 count, cells/mm3 371 (293–509) 378 (298–484) 196 (78–321) ,0.001 297 (160–408)
CD8 count, cells/mm3 998 (692–1188) 952 (710–1274) 841 (557–1160) 0.026 895 (622–1207)
CD4/CD8 count, cells/mm3 0.39 (0.35–0.48) 0.41 (0.30–0.56) 0.23 (0.12–0.35) ,0.001 0.33 (0.19–0.46)
IL-6, pg/mL 1.7 (1.2–4.2) 1.4 (0.8–2.5) 1.9 (1.1–3.4) ,0.001 1.7 (1.0–2.9)
sCD14, pg/mL 2.8 (2.2–4.0) 2.7 (1.9–3.3) 2.9 (2.1–4.0) 0.032 2.8 (2.1–3.8)
Year of stored sample 2011 (2010–2012) 2011 (2008–2011) 2010 (2003–2011) ,0.001 2010 (2004–2011)
White blood cells, 1000/mm3 5400 (4300–6900) 5250 (4420–5900) 4400 (3300–5685) ,0.001 4990 (3810–5900)
HIV DNA, copies per 1%106 CD4 cells 618 (371–786) 4029 (2576–6520) 34 876 (17 692–82 539) ,0.001 10 702 (3397–36 632)
HBsAg, n (%) 0.236
negative 34 (77.3) 135 (83.3) 195 (85.9) 364 (84.1)
positive 1 (2.3) 0 (0.0) 1 (0.4) 2 (0.5)
not tested 9 (20.5) 27 (16.7) 31 (13.7) 67 (15.5)
CMV, n (%) 0.771
negative 2 (4.5) 9 (5.6) 14 (6.2) 25 (5.8)
positive 23 (52.3) 76 (46.9) 120 (52.9) 219 (50.6)
not tested 19 (43.2) 77 (47.5) 93 (41.0) 189 (43.6)
HCV Ab, n (%) 0.897
negative 34 (77.3) 121 (74.7) 178 (78.4) 333 (76.9)
positive 6 (13.6) 24 (14.8) 26 (11.5) 56 (12.9)
not tested 4 (9.1) 17 (10.5) 23 (10.1) 44 (10.2)
HBsAg, Hepatitis B surface antigen; CMV, Cytomegalovirus.
Unless otherwise indicated, results shown are median (IQR).
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.10 000 copies/106 CD4! T cells than in those with pre-ART HIV
DNA in the ranges 1000–10 000 and 10–1000 copies/106 CD4! T
cells (Table 1). As expected, correlations between higher levels of
pre-ART HIV DNA and (i) higher plasma HIV RNA; (ii) lower CD4! T
cell count; and (iii) lower CD4/CD8 ratio, all collected at baseline of
ART, were confirmed by significant linear correlations (Pearson R2
and P values:!0.44 and,0.0001;#0.58 and,0.0001; and#0.48
and,0.0001, respectively) (Figure 1). Conversely, less strong corre-
lations were found between HIV DNA and IL-6 (P"0.002), sCD14
(P"0.05) and CD8! T cells (P"0.01) (Figure 1).
Role of pre-ART HIV DNA in influencing treatment
outcome
Kaplan–Meier curves and Cox regression multivariable analyses
were performed to characterize the association between pre-ART
HIV DNA and therapy outcomes in our study population.
Association between pre-ART HIV DNA and time to achieve
virological suppression 50 copies/mL
Of the 433 patients analysed, 397 achieved virological suppres-
sion. In particular, the probability of achieving plasma HIV RNA
50 copies/mL by 12 and 24 months after starting ART was 73.6%
(95% CI 69.3–77.8) and 92.1% (95% CI 89.4–94.9), respectively.
By stratifying patients according to pre-ART HIV DNA levels, we
found that the cumulative probability of virological suppression
was significantly lower in the group starting ART with the highest
HIV DNA (Figure 2). In particular, the proportion of patients reach-
ing virological suppression was 67.2% (95% CI 60.9–73.5) in
the pre-ART HIV DNA .10 000 copies/106 CD4! T cells group,
81.1% (95% CI 75.0–87.3) in the pre-ART HIV DNA 1000–10 000
copies/106 CD4! T cells group and 86.4% (95% CI 75.4–97.3) in
the pre-ART HIV DNA 10–1000 copies/106 CD4! T cells group
(P"0.0004 by Fleming–Harrington test). Further, the estimated
median time to achieve virological suppression in patients with a
pre-ART HIV DNA.10 000 copies/106 CD4! T cells was significant-
ly longer than that observed in the remaining two groups [median
time to reach virological suppression: 10.0 (IQR 9–11) months for
patients with HIV DNA .10 000 copies/106 CD4! T cells; 8.0 (IQR
7–9) months for patients with 1000–10 000 copies/106 CD4! T
cells; and 8.0 (IQR 6–9) months for patients with 10–1000 copies/
106 CD4! T cells] (Figure 2).
Overall, by 6 months of treatment the percentage of patients
with HIV RNA50 copies/mL was low, probably due to a large pro-
portion of patients starting treatment with less potent ART. At
6 and 12 months there was a statistically significant difference in
the percentage of patients who were virologically suppressed
according to the three different HIV DNA strata [patients with
plasma HIV RNA 50 copies/mL at 6 months after starting ART
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Figure 1. Linear correlations of pre-ART HIV DNA with viro-immunological parameters at baseline of ART in first-line treated ART patients.
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were 18/42 (43%), 53/153 (35%) and 32/215 (15%), and at
12 months were 31/36 (86%), 127/142 (89%) and 137/198 (69%),
respectively, for baseline HIV DNA of 10–1000, 1000–10 000 and
.10 000 copies/106 CD4! T cells; false discovery rate (FDR)
P,0.0001 at both timepoints].
Association of pre-ART HIV DNA with the virological
rebound
By considering the 397 patients achieving virological suppression,
the probability of experiencing virological rebound, defined by two
confirmed plasma HIV RNA determinations .50 copies/mL, was
12% (95% CI 8.6–15.5). By stratifying patients for the three differ-
ent pre-ART HIV DNA levels, increasing rates of virological rebound
were found with increasing pre-ART HIV DNA (P"0.0048 by
Fleming–Harrington test) (Figure 3). In particular, by 12 and
24 months the proportion of patients experiencing virological re-
bound for those with a pre-ART HIV DNA.10 000 copies/106 CD4!
T cells was significantly higher than that observed in the remaining
two patient categories [15.2% (95% CI 10.1–20.3) by 12 months
and 17.2% (95% CI 11.7–22.6) by 24 months for patients with HIV
DNA .10 000 copies/106 CD4! T cells; 4.8% (95% CI 1.3–8.2) by
12 months and 7.4% (95% CI 2.9–1.8) by 24 months for patients
with 1000–10 000 copies/106 CD4! T cells; and 0.0% (95% CI
0.0–0.0) by 12 months and 4.3% (95% CI: 0–12.7) by 24 months
for those with 10–1000 copies/106 CD4! T cells]. The results were
similar using different definitions of virological rebound, such as
two confirmed plasma HIV RNA determinations .200 copies/mL
or a single HIV RNA determination .1000 copies/mL, even if the
P values by Fleming–Harrington tests were not significant (P"0.20
and P"0.16, respectively; data not shown).
Association of pre-ART HIV DNA with increase in CD4!
T cell count and with clinical events
From ART initiation to follow-up, 83.4% (95% CI 79.4–87.4) of
the 433 individuals increased their CD4! T cells by at least
200 cells/mm3 and 2.7% (95% CI 1.1–4.3) of patients experienced
an AIDS diagnosis, serious non-AIDS event or death. The survival
analyses by the Kaplan–Meier curves showed that there was no
evidence for a difference in the rates of CD4! T cell gain and in the
risk of AIDS diagnosis, serious non-AIDS events or death by
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Figure 2. Kaplan–Meier probability estimates of achieving plasma HIV-1 RNA 50 copies/mL. Statistically significant difference was assessed by the
Fleming–Harrington test. Analysis was performed on 433 patients.
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increasing levels of pre-ART HIV DNA (P"0.95 and P"0.11, by
Fleming–Harrington test, respectively; data not shown).
Relative prognostic value of pre-ART HIV DNA and HIV
RNA to predict treatment outcome
In order to directly compare the relative prognostic value of pre-
ART HIV DNA and pre-ART HIV RNA for virological suppression and
long-term virological rebound, first we created a bivariable Cox re-
gression model including only these two factors, both fitted to the
log10 scale (Table 2). We then proceeded to perform the compari-
son after controlling for potential confounding factors (three sep-
arate sets of confounders) (Table 3).
Prognostic value of pre-ART HIV DNA and pre-ART HIV RNA
on the chance of virological suppression and risk of devel-
oping clinical events
By the initial bivariable analysis, higher pre-ART HIV DNA and
higher pre-ART HIV RNA were both associated with a lower hazard
of virological suppression, the magnitude of the effect being
slightly higher for HIV DNA [HR per log10 increase 0.84 (95% CI
0.72–0.97) and 0.74 (0.64–0.85), respectively] (Table 2). However,
after controlling for other confounding factors, only pre-ART HIV
RNA remained independently associated with the probability of
virological suppression (P,0.0001 in both models A and B) and
weakly associated with the CD4! T cell count recovery (raw P val-
ue"0.028 in model A and 0.011 in model B) (Table 3).
Of note, HIV DNA was associated with the risk of AIDS diagnosis
or the occurrence of a serious non-AIDS event or death after con-
trolling for HIV RNA alone (Table 2), but neither viral parameter
was associated with this outcome after further adjusting for the
other factors (Table 3).
Prognostic value of pre-ART HIV DNA and pre-ART HIV RNA
on virological rebound
Looking at the risk of virological rebound in people who initially
achieved virological suppression, in the bivariable model, only
patients with a higher pre-ART HIV DNA were at higher risk of viro-
logical rebound, for all definitions of rebound (confirmed.50 cop-
ies/mL, confirmed .200 copies/mL or single .1000 copies/mL),
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Figure 3. Kaplan–Meier probability estimates of achieving virological rebound, defined as two confirmed plasma HIV RNA determinations .50 cop-
ies/mL, after the virological suppression. Statistically significant difference was assessed by the Fleming–Harrington test. Analysis was performed on
397 patients.
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independent of pre-ART HIV RNA [HR 1.96 (95% CI 1.32–2.92); 2.94
(95% CI 1.58–5.47); and 2.24 (95% CI 1.36–3.70), respectively]. In
contrast, after controlling for HIV DNA, pre-ART HIV RNA was not
associated with the risk of viral rebound whichever definition was
used (Table 2). Interestingly, in all three models, with adjustment
for other confounding factors, higher pre-ART HIV DNA was con-
firmed to be the only factor to have a strong prognostic value for
viral rebound, whichever definition was applied for it (Table 3). In
particular, when virological rebound was defined as a single deter-
mination of plasma HIV RNA .1000 copies/mL or two confirmed
plasma determinations of HIV RNA .200 copies/mL, the risk that
this event occurred in patients with a pre-ART HIV DNA.1000 cop-
ies/106 CD4! T cells was more than 2-fold or even 4-fold higher
(according to these two virological rebound definitions) than in
patients with a pre-ART HIV DNA ,1000 copies/106 CD4! T cells.
Interestingly, this association was also found using the third model
with final adjustment for antiretrovirals being stopped prior to
achieving VL 50 copies/mL, time to achieve VL50 copies/mL,
total number of drugs used prior to VL50 copies/mL and the GSS
(Table 3).
Discussion
In this study, we performed a comprehensive evaluation of the
role of pre-ART HIV DNA, defined as the total HIV DNA normalized
by CD4! T cell count, in the treatment outcome of patients start-
ing first-line ART. The most important finding of our study is that in
people who originally achieved viral suppression 50 copies/mL,
pre-ART HIV DNA level was a strong and significant predictor of
virological rebound. Indeed, Cox multivariable estimates
confirmed that pre-ART HIV DNA/106 CD4! T cells, and not pre-
ART HIV RNA, was an independent factor associated with faster
virological rebound: 1 log10 HIV DNA higher resulted in a 4-fold
higher risk of virological rebound, with an HIV RNA threshold of
200 copies/mL.
So far the predictive value of total HIV DNA in treatment out-
comes, such as virological rebound, immune recovery and cell acti-
vation status, and also in the setting of de-escalation, has been
evaluated in extensively ART-pretreated populations.7,17–22,31
Few studies have clearly defined the role of total HIV DNA when
measured in drug-naive patients before first ART initiation.
Previous papers have mainly focused on heterogeneous popula-
tions typically of small sample size.23–25,32 For example, a pro-
spective multicentre study has tried to assess the predictive value
of PBMC HIV-1 DNA for determining virological and immunological
outcomes in a cohort of 148 patients who were treated (starting
from 1998) with a first-line PI-containing regimen. This analysis
showed that a higher baseline HIV-1 DNA level was associated
with an increased risk of virological failure after 1 year of ART, inde-
pendently of other factors considered.23 The Monark study showed
that, analysing baseline HIV DNA in whole blood using real-time
PCR in 46 antiretroviral-naive patients receiving lopinavir/ritonavir
monotherapy, the non-responders (with HIV RNA .50 copies/mL)
at 48 weeks had significantly higher baseline HIV-1 DNA load than
responders (HIV RNA 50 copies/mL).24 In our analysis, we found
a direct association between pre-ART total HIV DNA and the risk of
virological rebound, after virological suppression during therapy, in
a large cohort of patients starting ART. Moreover, this association
was independent of pre-ART plasma HIV RNA and CD4! T cell
count, suggesting that HIV DNA contains information related to
Table 2. Relative prognostic value of 1 log10 higher pre-ART HIV DNA and pre-ART HIV RNA in uni- and bivariable Cox analyses
HRs associated with 1 log10 increase in the markers from fitting a Cox regression model
pre-ART HIV DNA pre-ART HIV RNA
unadjusted mutually adjusted unadjusted mutually adjusted
VL 50 copies/mL 0.76 (0.66–0.87) 0.84 (0.72–0.97) 0.70 (0.61–0.80) 0.74 (0.64–0.85)
raw P value ,0.0001 0.018 ,0.0001 ,0.0001
FDR-adjusted P value 0.0006 0.033 0.0006 0.0006
CD4! T cell count gain .200 cells/mm3 above pre-ART 0.93 (0.81–1.07) 0.87 (0.75–1.02) 1.11 (0.96–1.28) 1.17 (1.00–1.36)
raw P value 0.325 0.077 0.154 0.046
FDR-adjusted P value 0.371 0.123 0.231 0.079
VL rebound
confirmed.50 copies/mL 2.20 (1.54–3.15) 1.96 (1.32–2.92) 1.66 (1.12–2.47) 1.27 (0.84–1.93)
raw P value ,0.0001 0.0008 0.012 0.258
FDR-adjusted P value 0.0006 0.003 0.024 0.310
confirmed.200 copies/mL 2.42 (1.37–4.29) 2.94 (1.58–5.47) 0.98 (0.56–1.73) 0.67 (0.37–1.21)
raw P value 0.002 0.0007 0.948 0.184
FDR-adjusted P value 0.006 0.003 0.948 0.245
single value .1000 copies/mL 1.93 (1.20–3.08) 2.24 (1.36–3.70) 0.93 (0.60–1.45) 0.73 (0.46–1.14)
raw P value 0.006 0.002 0.750 0.168
FDR-adjusted P value 0.013 0.006 0.818 0.237
AIDS, serious non-AIDS events or death 2.70 (1.41–5.17) 2.79 (1.36–5.74) 1.51 (0.78–2.92) 0.97 (0.48–1.95)
raw P value 0.003 0.005 0.221 0.927
FDR-adjusted P value 0.008 0.012 0.279 0.948
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the patient’s total viral burden that has prognostic value over and
above what is currently used to calculate patient failure risk score
in clinical practice. A similar finding, although for a much smaller
cohort, had previously been reported by Hatzakis et al.25 In that
paper, cellular HIV-1 DNA load was the only parameter associated
with the chance of achieving sustained virological response in peo-
ple starting treatment from being ART-naive. In other words, our
analysis confirms the role of pre-ART HIV RNA to predict initial viro-
logical response to treatment,17,33 while diminishing its role as a
predictor of viral rebound, once HIV DNA is accounted for.
On the basis of our results, the quantification of HIV DNA levels
in CD4! T cells before therapy should be considered, besides what
is currently used in the clinics, to help identify people at lower (or
higher) risk of viral rebound following achievement of suppression.
Our data also provide indirect evidence to guide the choice of first
treatment in ART-naive individuals.
For instance, it is known that, compared with other available drug
classes, the inclusion of an integrase strand transfer inhibitor (INSTI)
in first-line combinations is associated with faster HIV-1 VL decay34
and a larger reduction of total HIV-1 DNA in virologically suppressed
HIV-1-infected patients.35 On the basis of our results it could be
argued that the use of an INSTI is appropriate in patients with high
baseline levels of HIV DNA and that their use may have long-term
benefits by reducing HIV DNA in people with controlled HIV RNA.
Interestingly, higher levels of pre-ART HIV DNA showed a good
correlation with higher levels of several inflammatory markers
associated with T cell immune activation, such as IL-6, sCD14 and
CD8! T cells, supporting the association between HIV DNA and
systemic inflammation, and thus clinical progression. These results
are, however, in contrast with a recent paper published by Gandhi
et al.,36 showing that levels of HIV DNA (pre-ART and during ther-
apy) are not associated with different levels of inflammatory bio-
markers such as IL-6, sCD14 and sCD163. Because of these
conflicting findings, studies including higher numbers of patients
will be necessary to estimate the real role of HIV DNA in the inflam-
matory process and thus to better understand the role of this par-
ameter in the definition of the inflammatory process and thus
clinical progression.
In addition, it needs to be noted that, to date, the major prob-
lem with measuring HIV DNA is the lack of reproducibility of differ-
ent tests and different samples used for the analysis. Currently,
there are different in-house protocols to quantify HIV DNA starting
from CD4! T cells, PBMC or whole blood, by measuring total HIV
DNA, proviral-integrated or two long terminal repeats (2 LTRs) and
few commercial assays (so far there is a commercial kit ‘Generic
HIV DNA Cell’ from Biocentric, Bandol, France, largely used in
France, and another recently developed from Diatheva, HIV-1 DNA
qPCR kit, for research use only). For our analysis we used a modified
Table 3. Relative prognostic value of 1 log10 higher pre-ART HIV DNA and pre-ART HIV RNA in multivariable Cox analyses
HRs associated with 1 log10 increase in the markers from fitting a Cox regression model
HIV DNA HIV RNA
Characteristic adjusteda adjustedb adjustedc adjusteda adjustedb adjustedc
VL 50 copies/mL 0.98 (0.82–1.16) 0.96 (0.80–1.15) 0.74 (0.66–0.83) 0.75 (0.67–0.85)
raw P value 0.796 0.674 ,0.001 ,0.001
FDR-adjusted P value 0.839 0.749 0.004 0.004
CD4 count gain .200 cells/mm3
above pre-ART
0.91 (0.76–1.08) 0.88 (0.73–1.05) 1.15 (1.01–1.30) 1.17 (1.04–1.33)
raw P value 0.282 0.164 0.028 0.011
FDR-adjusted P value 0.368 0.289 0.065 0.03
VL rebound
confirmed.50 copies/mL 1.76 (1.09–2.82) 1.95 (1.18–3.22) 1.94 (1.16–3.25) 1.25 (0.89–1.76) 1.13 (0.80–1.61) 1.19 (0.81–1.75)
raw P value 0.020 0.009 0.011 0.198 0.492 0.386
FDR-adjusted P value 0.05 0.03 0.03 0.312 0.568 0.463
confirmed.200 copies/mL 4.05 (1.82–9.02) 5.65 (2.37–13.49) 4.88 (2.01–11.83) 0.79 (0.52–1.21) 0.72 (0.45–1.14) 0.75 (0.45–1.24)
raw P value ,0.001 ,0.001 ,0.001 0.280 0.161 0.259
FDR-adjusted P value 0.0043 0.0043 0.0043 0.368 0.289 0.368
single value .1000 copies/mL 2.56 (1.33–4.92) 4.01 (1.92–8.39) 3.75 (1.78–7.93) 0.79 (0.56–1.12) 0.74 (0.51–1.09) 0.72 (0.47–1.12)
raw P value 0.005 ,0.001 ,0.001 0.182 0.133 0.142
FDR-adjusted P value 0.019 0.0043 0.0043 0.303 0.284 0.284
AIDS, serious non-AIDS events
or death
1.60 (0.66–3.89) 1.85 (0.71–4.80) 0.99 (0.54–1.82) 0.92 (0.45–1.88)
raw P value 0.297 0.208 0.986 0.811
FDR-adjusted P value 0.371 0.312 0.986 0.839
aAdjusted for calendar year of ART, type of regimen started, CD4 count and RNA/DNA at ART.
bAdjusted for calendar year of ART, type of regimen started, CD4 count, RNA/DNA at ART, age, smoking, HCV status, IL-6 and sCD14.
cAdjusted for calendar year of ART, type of regimen started, CD4 count, RNA/DNA at ART, age, smoking, HCV status, whether person had stopped anti-
retrovirals prior to achieving VL50 copies/mL, time to achieve VL50 copies/mL, total number of drugs used prior to baseline and HIV database
GSS of baseline regimen.
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commercial assay measuring both integrated, long-lived proviral
DNA and unintegrated short-lived HIV DNA.10 Unlike the other
assays described in this paragraph, this assay is simple and may be
routinely applied, because it is already largely used in clinical prac-
tice for HIV RNA measurement all over the world.
A possible limitation of our analysis is the lack of adherence
data, which is a known determinant of virological response to ART,
particularly in the presence of larger reservoir sizes. On the other
hand, it is unlikely that adherence level is associated with HIV DNA
burden in individual patients before starting ART. Of note, the ana-
lysis of the risk of viral rebound is restricted to people who did
achieve viral suppression 50 copies/mL on ART. When we com-
pared the characteristics of people who ever achieved HIV
RNA50 copies/mL (included in the time to rebound analysis) and
those who never achieved viral suppression (excluded), we found
that included patients were more likely to be hepatitis-negative,
MSM and of Italian origin (Table S2). These data confirm that
patients evaluated for time to viral rebound analysis were a
selected population of participants who are more likely to be ad-
herent to treatment. Therefore, selection bias cannot be ruled out
and it needs to be acknowledged that the results of our main ana-
lysis are only applicable to populations presumed to have good ad-
herence to treatment.
In conclusion, pre-ART HIV DNA showed strong clinical rele-
vance as a marker of HIV burden and reservoir and, although it is
unable to distinguish between replication-competent and
replication-defective viral forms, it appears to be useful to predict
the course of the infection and also under-exposure to ART.
Measurement of HIV DNA while a person is still untreated should
be considered both to inform treatment choices and help predict
the long-term efficacy of ART. Moreover, in the absence of other
sensitive and reproducible tests, because the assay used in our
analysis is simple, rapid and easily obtainable on the market, it
stands as a promising candidate for standardization and measure-
ment of the HIV reservoir in clinical practice.
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